Overview: Aldolase TestIntroduction: The Aldolase Test measures aldolase, an enzyme, to detect muscle damage or diseases like muscular dystrophy, which can cause muscle pain, weakness, or cramps. Following 2023 clinical biochemistry guidelines, it uses spectrophotometry for high accuracy, aiding in diagnosing muscle disorders. This test is critical for guiding supportive therapies, preventing complications, and improving outcomes in neuromuscular health.
Other Names: Aldolase Assay, Muscle Enzyme Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: Aldolase was linked to muscle damage in the 1950s. Spectrophotometry emerged in the 1970s, and by the 2000s, automated assays improved clinical utility.
Purpose: Diagnoses muscle disorders, guides therapy, and monitors disease in patients with muscle pain or weakness.
Test Parameters: 1. Aldolase
Pretest Condition: Fasting for 10-12 hours is required. Collect serum or plasma at any time. Report muscle pain, weakness, or recent physical exertion.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document muscle pain, weakness, cramps, or family history of muscle disorders. Include recent exercise or medications.
Consent: Written consent required, explaining the test's purpose, diagnostic implications, and potential therapy needs.
Procedural Considerations: Uses spectrophotometry to measure aldolase levels. Results are available in 1-2 days, supporting rapid diagnosis.
Factors Affecting Result Accuracy: Recent exercise or trauma may elevate aldolase levels. Hemolysis or improper storage can degrade samples.
Clinical Significance: Elevated aldolase suggests muscle damage or dystrophy, prompting further testing or therapy. Normal levels may require repeat testing.
Specialist Consultation: Consult a neurologist or rheumatologist for result interpretation. Genetic counseling is advised for suspected dystrophies.
Additional Supporting Tests: Creatine kinase, electromyography, or muscle biopsy to confirm muscle disorders.
Test Limitations: Non-specific aldolase elevation requires clinical correlation. Early disease may not elevate levels significantly.
References: AANEM Neuromuscular Guidelines, 2023; Darras BT, Neurology, 2022.
